Increased Risk of Cerebrovascular Adverse Events and Death in Elderly Demented Patients Treated With Atypical Antipsychotics: What's a Clinician to Do?

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Recent U.S. Food and Drug Administration(FDA) warnings of increased risk ofcerebrovascular adverse events (CVAEs) andincreased mortality with atypical antipsychoticsin older patients with dementia havereceived considerable attention and resultedin black box warnings for this drug class.Clinicians who treat these patients havea challenging clinical dilemma. Behavioralproblems in this patient group can be severeand can result in nursing home placement.’ ‹